First clinical data for arcus biosciences' hif-2a inhibitor, casdatifan, showed promising clinical activity and tumor shrinkage in patients with metastatic kidney cancer

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a hif-2a inhibitor with best-in-class potential, in an oral plenary session by dr. toni k. choueiri, dana-farber cancer institute at the 2024 eortc-nci-aacr symposium on molecular targets and cancer therapeutics i.
RCUS Ratings Summary
RCUS Quant Ranking